BACKGROUND: ES-285 (spisulosine) is a novel compound derived from the marine mollusk Spisula polynoma with evidence of preclinical antitumor activity. This phase I clinical trial was designed to identify the maximum tolerated dose (MTD) and the recommended dose for phase II trials (RD), as well as to evaluate the safety profile, pharmacokinetics and preliminary efficacy data of ES-285 in patients with advanced solid tumors. PATIENTS AND METHODS: Sixty-one patients at two medical institutions were treated with a 3-h ES-285 intravenous infusion every 3 weeks. Nine dose levels were evaluated. RESULTS: No dose-limiting toxicities (DLTs) were observed during dose escalation from 4 to 128 mg/m(2). Six patients had seven DLTs at the three highest dose levels tested: 256 mg/m(2) (n = 2), 200 mg/m(2) (n = 3) and 160 mg/m(2) (n = 1). Grade 3/4 transaminase increases (n = 3), grade 3/4 central nervous system disorders [confusion (n = 2) and ataxia (n = 1)], and grade 3 pyrexia (n = 1) were the dose-limiting toxicities found with this ES-285 administration schedule. Pharmacokinetic analysis showed ES-285 dose linearity, wide distribution and a long half-life. One non-confirmed partial response was observed in a patient with metastatic melanoma treated with ES-285 128 mg/m(2), and 18 patients showed stable disease at different dose levels, lasting longer than 3 months in six patients. CONCLUSION: Dose level VIII (200 mg/m(2)) was considered the MTD, and dose level IX (160 mg/m(2)) was defined as the RD. Limited antitumor activity was observed.
BACKGROUND:ES-285 (spisulosine) is a novel compound derived from the marine mollusk Spisula polynoma with evidence of preclinical antitumor activity. This phase I clinical trial was designed to identify the maximum tolerated dose (MTD) and the recommended dose for phase II trials (RD), as well as to evaluate the safety profile, pharmacokinetics and preliminary efficacy data of ES-285 in patients with advanced solid tumors. PATIENTS AND METHODS: Sixty-one patients at two medical institutions were treated with a 3-h ES-285 intravenous infusion every 3 weeks. Nine dose levels were evaluated. RESULTS: No dose-limiting toxicities (DLTs) were observed during dose escalation from 4 to 128 mg/m(2). Six patients had seven DLTs at the three highest dose levels tested: 256 mg/m(2) (n = 2), 200 mg/m(2) (n = 3) and 160 mg/m(2) (n = 1). Grade 3/4 transaminase increases (n = 3), grade 3/4 central nervous system disorders [confusion (n = 2) and ataxia (n = 1)], and grade 3 pyrexia (n = 1) were the dose-limiting toxicities found with this ES-285 administration schedule. Pharmacokinetic analysis showed ES-285 dose linearity, wide distribution and a long half-life. One non-confirmed partial response was observed in a patient with metastatic melanoma treated with ES-285 128 mg/m(2), and 18 patients showed stable disease at different dose levels, lasting longer than 3 months in six patients. CONCLUSION: Dose level VIII (200 mg/m(2)) was considered the MTD, and dose level IX (160 mg/m(2)) was defined as the RD. Limited antitumor activity was observed.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Monique W J Den Brok; Bastiaan Nuijen; Dieuwke M Meijer; Elena Millán; Consuelo Manada; Jos H Beijnen Journal: PDA J Pharm Sci Technol Date: 2005 Jul-Aug
Authors: P Schöffski; H Dumez; R Ruijter; B Miguel-Lillo; A Soto-Matos; V Alfaro; G Giaccone Journal: Cancer Chemother Pharmacol Date: 2011-04-05 Impact factor: 3.333
Authors: Eduardo Vilar; Viktor Grünwald; Patrick Schöffski; Harald Singer; Ramon Salazar; Jose Luis Iglesias; Esther Casado; Martin Cullell-Young; Jose Baselga; Josep Tabernero Journal: Invest New Drugs Date: 2010-09-07 Impact factor: 3.850
Authors: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; Jan H M Schellens; Jos H Beijnen Journal: Biomed Chromatogr Date: 2004-07 Impact factor: 1.902
Authors: Richard D Baird; Jos Kitzen; Paul A Clarke; Andre Planting; Sarah Reade; Alison Reid; Lyndsey Welsh; Luis López Lázaro; Begona de las Heras; Ian R Judson; Stan B Kaye; Ferry Eskens; Paul Workman; Johann S deBono; Jaap Verweij Journal: Mol Cancer Ther Date: 2009-06-09 Impact factor: 6.261
Authors: E Stokvis; L Nan-Offeringa; H Rosing; L López-Lázaro; J L Aceña; E Miranda; A Lyubimov; B S Levine; C D'Aleo; J H M Schellens; J H Beijnen Journal: J Mass Spectrom Date: 2003-05 Impact factor: 1.982
Authors: Stefka D Spassieva; Xiaojie Ji; Ye Liu; Kenneth Gable; Jacek Bielawski; Teresa M Dunn; Erhard Bieberich; Lihong Zhao Journal: Proc Natl Acad Sci U S A Date: 2016-05-09 Impact factor: 11.205
Authors: Maria Letizia Ciavatta; Florence Lefranc; Marianna Carbone; Ernesto Mollo; Margherita Gavagnin; Tania Betancourt; Ramesh Dasari; Alexander Kornienko; Robert Kiss Journal: Med Res Rev Date: 2016-12-07 Impact factor: 12.944
Authors: Irina Alecu; Andrea Tedeschi; Natascha Behler; Klaus Wunderling; Christian Lamberz; Mario A R Lauterbach; Anne Gaebler; Daniela Ernst; Paul P Van Veldhoven; Ashraf Al-Amoudi; Eicke Latz; Alaa Othman; Lars Kuerschner; Thorsten Hornemann; Frank Bradke; Christoph Thiele; Anke Penno Journal: J Lipid Res Date: 2016-11-23 Impact factor: 5.922
Authors: Nicholas U Schwartz; Izolda Mileva; Mikhail Gurevich; Justin Snider; Yusuf A Hannun; Lina M Obeid Journal: Prostaglandins Other Lipid Mediat Date: 2019-02-19 Impact factor: 3.072
Authors: Noemi Jiménez-Rojo; Jesús Sot; Jon V Busto; Walt A Shaw; Jingjing Duan; Alfred H Merrill; Alicia Alonso; Félix M Goñi Journal: Biophys J Date: 2014-12-16 Impact factor: 4.033
Authors: Samar M Hammad; Nathaniel L Baker; Jad M El Abiad; Stefanka D Spassieva; Jason S Pierce; Barbara Rembiesa; Jacek Bielawski; Maria F Lopes-Virella; Richard L Klein Journal: Neuromolecular Med Date: 2016-07-07 Impact factor: 3.843